Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=24797827
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Amniotic fluid-derived mesenchymal stem cells prevent fibrosis and preserve renal
function in a preclinical porcine model of kidney transplantation
#MMPMID24797827
Baulier E
; Favreau F
; Le Corf A
; Jayle C
; Schneider F
; Goujon JM
; Feraud O
; Bennaceur-Griscelli A
; Hauet T
; Turhan AG
Stem Cells Transl Med
2014[Jul]; 3
(7
): 809-20
PMID24797827
show ga
It is well known that ischemia/reperfusion injuries strongly affect the success
of human organ transplantation. Development of interstitial fibrosis and tubular
atrophy is the main deleterious phenomenon involved. Stem cells are a promising
therapeutic tool already validated in various ischemic diseases. Amniotic
fluid-derived mesenchymal stem cells (af-MSCs), a subpopulation of multipotent
cells identified in amniotic fluid, are known to secrete growth factors and
anti-inflammatory cytokines. In addition, these cells are easy to collect,
present higher proliferation and self-renewal rates compared with other adult
stem cells (ASCs), and are suitable for banking. Consequently, af-MSCs represent
a promising source of stem cells for regenerative therapies in humans. To
determine the efficiency and the safety of af-MSC infusion in a preclinical
porcine model of renal autotransplantation, we injected autologous af-MSCs in the
renal artery 6 days after transplantation. The af-MSC injection improved
glomerular and tubular functions, leading to full renal function recovery and
abrogated fibrosis development at 3 months. The strong proof of concept generated
by this translational porcine model is a first step toward evaluation of
af-MSC-based therapies in human kidney transplantation.
free
free
free
